Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice

doi:10.1016/j.jbc.2022.101946

科研成果详情

题名	Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice
作者	Yuan, Youwen 1,2; Li, Kangli 1,2; Teng, Fei 1,2; Wang, Weiwei 1,2; Zhou, Bing 3; Zhou, Xuan 1,2; Lin, Jiayang 1,2; Ye, Xueru 1,2; Deng, Yajuan 1,2; Liu, Wenhui 1,2; Luo, Shenjian 1,2; Zhang, Peizhen 1,2; Liu, Deying 1,2; Zheng, Minghua4,5; Li, Jin 6; Lu, Yan 3; Zhang, Huijie 1,2
发表日期	2022-06
发表期刊	Journal of Biological Chemistry 影响因子和分区
语种	英语
原始文献类型	Journal article (JA)
关键词	Amino acids Diseases Mammals Chronic liver disease Cytokines Interleukin6 (IL6) Leukaemia inhibitory factors Liver steatosis Molecular mechanism Non-alcoholic fatty liver disease Obese mice Physiological process Receptor signaling
其他关键词	INSULIN-RESISTANCE ; SELF-RENEWAL ; LIF ; THERAPY ; CANCER
摘要	Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. However, the molecular mechanisms that promote dysregulation of hepatic triglyceride metabolism and lead to NAFLD are poorly understood, and effective treatments are limited. Leukemia inhibitory factor (LIF) is a member of the interleukin-6 cytokine family and has been shown to regulate a variety of physiological processes, although its role in hepatic triglyceride metabolism remains unknown. In the present study, we measured circulating LIF levels by ELISA in 214 patients with biopsy-diagnosed NAFLD as well as 314 normal control patients. We further investigated the potential role and mechanism of LIF on hepatic lipid metabolism in obese mice. We found that circulating LIF levels correlated with the severity of liver steatosis. Patients with ballooning, fibrosis, lobular inflammation, and abnormally elevated liver injury markers alanine transaminase and aspartate aminotransferase also had higher levels of serum LIF than control patients. Furthermore, animal studies showed that white adipose tissue–derived LIF could ameliorate liver steatosis through activation of hepatic LIF receptor signaling pathways. Together, our results suggested that targeting LIF-LIF receptor signaling might be a promising strategy for treating NAFLD. © 2022 THE AUTHORS.
资助项目	National Key Research and Development Project [2018YFA0800404]; Natural Science Foundation [2018B030311031]; Key-Area Research and Development Program of Guangdong Province [2018B030311031]; National Natural Science Foundation of China [81970736, 81974119, 82070588]; Program of Shanghai Academic Research Leader by Shanghai Municipal Science and Technology Committee [21XD1423400]; Distinguished Young Scholars Training Program of Nanfang Hospital
出版者	American Society for Biochemistry and Molecular Biology Inc.
出版地	AMSTERDAM
ISSN	0021-9258
EISSN	1083-351X
卷号	298 期号:6 页码:101946
DOI	10.1016/j.jbc.2022.101946
页数	16
WOS类目	Biochemistry & Molecular Biology
WOS研究方向	Biochemistry & Molecular Biology
WOS记录号	WOS:000838892100006
收录类别	EI ; SCIE ; PUBMED ; SCOPUS
EI入藏号	20222212160556
EI主题词	Metabolism
EI分类号	804.1 Organic Compounds
URL	查看原文
PubMed ID	35447114
SCOPUSEID	2-s2.0-85130593471
通讯作者地址	[Lu, Yan]The Key Laboratory of Metabolism and Molecular Medicine,the Ministry of Education,Department of Endocrinology and Metabolism,Zhongshan Hospital,Fudan University,Shanghai,China ; [Zhang, Huijie]Department of Endocrinology and Metabolism,China
Scopus学科分类	Biochemistry;Molecular Biology;Cell Biology
TOP期刊	TOP期刊
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/153402
专题	附属第一医院
通讯作者	Lu, Yan; Zhang, Huijie
作者单位	1.Department of Endocrinology and Metabolism,Pakistan; 2.Guangdong Provincial Key Laboratory of Shock and Microcirculation,Nanfang Hospital,Southern Medical University,Guangzhou,China; 3.The Key Laboratory of Metabolism and Molecular Medicine,the Ministry of Education,Department of Endocrinology and Metabolism,Zhongshan Hospital,Fudan University,Shanghai,China; 4.MAFLD Research Center,Department of Hepatology,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,China; 5.Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease,Zhejiang Province,Wenzhou,China; 6.Division of Endocrinology,Department of Medicine,Shanxi Medical University affiliated Second Hospital,Taiyuan,China
推荐引用方式 GB/T 7714	Yuan, Youwen,Li, Kangli,Teng, Fei,et al. Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice[J]. Journal of Biological Chemistry,2022,298(6):101946.
APA	Yuan, Youwen., Li, Kangli., Teng, Fei., Wang, Weiwei., Zhou, Bing., ... & Zhang, Huijie. (2022). Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice. Journal of Biological Chemistry, 298(6), 101946.
MLA	Yuan, Youwen,et al."Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice".Journal of Biological Chemistry 298.6(2022):101946.